Table 1.
Control group (n = 11) | Obese group (n = 12) | |
---|---|---|
Male/female | 7/4 | 12/0 |
Age, years | 23 (18–27) | 21.5 (19–28) |
BMI, kg/m2 | 19.5 (18.1–21.7) | 35.7 (32.0–44.9)*** |
BFM, kg | 8.2 (6.0–14.9) | 41.8 (26.6–63.0)*** |
PBF, % | 14.6 (10.6–29.8) | 39.1 (26.4–48.6)*** |
Visceral fat thickness, mm | 23.2 (17.2–47.3) | 69.4 (39.8–92.1)*** |
Subcutaneous fat thickness, mm | 5.4 (3.2–9.9) | 15.8 (11.5–29.8)*** |
Existence of fatty liver (+/–) | 0/11 | 9/3 |
T-Bil, μmol/l | 15.4 (5.1–34.2) | 13.7 (6.8–35.9) |
AST, U/l | 17 (14–35) | 25 (15–89)** |
ALT, U/l | 12 (9–42) | 39.5 (13–189)*** |
γ-GTP, U/l | 17 (11–28) | 33.5 (14–133)** |
ChE, U/l | 276 (196–345) | 406 (306–479)*** |
FBG, mmol/l | 4.6 (4.3–5.1) | 4.8 (4.2–5.3) |
HbA1c, % | 5.0 (4.7–5.9) | 5.1 (4.5–5.6) |
Insulin, μIU/ml | 3.1 (2.2–6.4) | 12.1 (6.3–32.4)*** |
HOMA-IR | 0.7 (0.4–1.5) | 2.6 (1.5–6.9)*** |
T-CHO, mmol/l | 4.3 (3.7–5.5) | 4.9 (3.6–10.5) |
HDL-C, mmol/l | 1.6 (1.3–2.5) | 1.1 (0.8–1.3)*** |
LDL-C, mmol/l | 2.2 (1.2–3.5) | 3.4 (2.3–8.1)** |
TG, mmol/l | 0.5 (0.4–1.7) | 1.2 (0.5–3.6)** |
TP, g/l | 73 (69–82) | 73 (68–79) |
Alb, g/l | 47 (41–49) | 44 (40–48)* |
AMY, U/l | 74 (59–229) | 57.5 (36–75)** |
BUN, mmol/l | 4.2 (3.3–5.7) | 3.8 (2.7–5.2) |
Cre, μmol/l | 71.6 (47.7–84.9) | 67.6 (60.1–91.1) |
UA, μmol/l | 350.9 (148.7–452.0) | 443.1 (232.0–535.3)** |
CRP, mg/l | 0.2 (0.0–4.8) | 1.6 (0.2–28.1)** |
BFM = Body fat mass; PBF = percent body fat; T-Bil = total bilirubin; AST = aspartate aminotransferase; ALT = alanine aminotransferase; γ-GTP = γ-glutamyl transpeptidase; ChE = cholinesterase; FBG = fasting blood glucose; HbA1c = hemoglobin A1c; HOMA-IR = homeostasis model assessment of insulin resistance; T-CHO = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglyceride; TP = total protein; Alb = albumin; AMY = amylase; BUN = blood urea nitrogen; Cre = creatinine; UA = uric acid; CRP = C-reactive protein.
p < 0.05
p < 0.01
p < 0.001 versus the control group.